| Ytd | -8.94% | |
| 1y | -1.21% |
| Open | 1.64 | Prev Close | 1.64 | Low | 1.62 | High | 1.68 | Mkt Cap | 302.01M |
| Vol | 687.28K | Avg Vol | 2.10M | EPS | -1.33 | P/E | -1.23 | Forward P/E | -1.01 |
| Beta | 2.75 | Short Ratio | 4.59 | Inst. Own | 72.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.65 | 200-d Avg | 2.18 | 1yr Est | 11.77 |
NMRA News
Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the en
RBC Capital analyst Brian Abrahams maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform
Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the c
NEW YORK--(BUSINESS WIRE)--Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment
Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%. NEW
NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals
Neumora Therapeutics Inc. (NASDAQ:NMRA) on Monday said it is discontinuing development of its lead d
ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Neumora The
Neumora Therapeutics said on Monday it would stop developing its depression drug after two late-s
Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue developm
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clin
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topl
WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a cl
LOS ANGELES, April 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights l
Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) was the target of some unusual options t
Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable
LOS ANGELES--(BUSINESS WIRE)---- $NMRA--NMRA Investors Have Opportunity to Join Neumora Therapeutics
WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a cl
NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation.